Tumor Heterogeneity Shapes Survival Dynamics in Drug-Treated Cells, Revealing Size-Drifting Subpopulations
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Tumor cell subpopulations dynamically change size during drug treatment, creating a favorable environment for cancer growth and drug resistance. This rheostat-like behavior, observed in melanoma and other cancers, is linked to aldehyde dehydrogenase (ALDH) activity.
Area Of Science
- Oncology
- Cancer Biology
- Tumor Microenvironment
Background
- Tumor heterogeneity is a key challenge in cancer therapy.
- Subpopulations of cancer cells can exhibit distinct behaviors influencing treatment response.
- Aldehyde dehydrogenase (ALDH) activity is a marker for stem-like cancer cells.
Purpose Of The Study
- To demonstrate that distinct cancer cell subpopulations can dynamically alter their sizes in response to drug-induced environmental changes.
- To investigate if these fluctuations act as a rheostat, optimizing the tumor environment for growth and drug resistance.
- To explore the role of aldehyde dehydrogenase (ALDH) activity in mediating these population dynamics.
Main Methods
- Utilized melanoma cell subpopulations differing in ALDH activity in both cultured and tumor models.
- Investigated rapid epigenetic transitions between stem-cell-like high and nonstem-like low production states.
- Analyzed proportional changes in cell populations to achieve stable equilibrium.
- Measured aldehyde and reactive oxygen species (ROS) levels in relation to cell population dynamics.
Main Results
- Observed that ALDH-high and ALDH-low subpopulations epigenetically transition, altering their production states.
- Demonstrated that cell population size fluctuations create an environment conducive to cellular proliferation and tumor expansion.
- Showed that these dynamic changes are mediated by ALDH enzyme activity and are dependent on drug-induced tumor stress.
- Found similar phenomena across multiple cancer types, not limited to melanoma.
Conclusions
- Cancer cell subpopulations can dynamically fluctuate in size, functioning as a rheostat to promote tumor growth and drug resistance.
- These fluctuations are mechanistically linked to managing aldehyde and ROS levels for optimal proliferation.
- This study is the first to report dynamic cell population size fluctuations as a cooperative mechanism in developing drug resistance.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...